3/9
08:51 am
veru
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss [Yahoo! Finance]
Low
Report
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss [Yahoo! Finance]
3/9
08:30 am
veru
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
Low
Report
Veru Enrolls First Patient in Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide Combination for High Quality Weight Loss
2/19
08:30 am
veru
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
Medium
Report
Veru to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference
2/12
10:35 am
veru
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
Medium
Report
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges [Yahoo! Finance]
2/11
01:56 pm
veru
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript [Seeking Alpha]
Medium
Report
Veru Inc. (VERU) Q1 2026 Earnings Call Transcript [Seeking Alpha]
2/11
06:30 am
veru
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
Neutral
Report
Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress
2/4
08:30 am
veru
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
Low
Report
Veru to Report Fiscal 2026 First Quarter Financial Results on February 11th
1/31
01:33 am
veru
Low
Report
1/23
05:09 am
veru
Veru (NASDAQ:VERU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Veru (NASDAQ:VERU) had its "sell (e+)" rating reaffirmed by analysts at
Weiss Ratings.
12/20
01:30 am
veru
Low
Report